Butchertown Clinical Trials

Butchertown Clinical Trials

Research

Louisville, Kentucky 299 followers

A dedicated multi-specialty clinical trials research site located in Louisville, KY. Now with 15 FDA approvals.

About us

We are a dedicated multi-specialty research site conducting clinical trials in Ophthalmology, Artificial Intelligence, Oncology, Human Genomics, Endocrinology, Medical Devices, and more. Investigators are Board Certified in their respective specialty and are trained in GCP. All of our clinical studies are done with the ultimate goal of getting the medication, treatment, implant, or device to become approved by the United States Food & Drug Administration (FDA). We're behind twelve FDA approvals, and our site provides valid and accurate data. We take your health, wellness, and vision very seriously. We carefully review all trials to ensure the health and well-being of our Louisville, KY area participants are protected. We participate in Proof of Concept, Phase I, Phase II, III, and IV trials, along with post-marketing studies.

Industry
Research
Company size
2-10 employees
Headquarters
Louisville, Kentucky
Type
Privately Held
Founded
1984

Locations

Employees at Butchertown Clinical Trials

Updates

  • Olivia Kaiser promoted to Clinical Trials Site Manager Olivia Kaiser, who began her career in clinical trials as a subject recruiter and was promoted to Clinical Trials Team Lead, has been promoted to Site Manager at Butchertown Clinical Trials. In Olivia’s new role, she will have expanded planning and trial coordination duties as the site is poised for additional growth and is currently expanding, allowing it to double the number of subjects screened for enrollment in new trials. "I am delighted to take on this new role as Site Manager at Butchertown Clinical Trials, where I can leverage my passion for advancing medical knowledge and improving patient outcomes. I plan to continue leading our team with a commitment to excellence; my goals include streamlining our research processes and resources, enhancing patient enrollment and engagement, and ensuring the highest level of data integrity and quality for our sponsors," Olivia said. Olivia earned a Bachelor of Arts in Psychology at the University of Louisville. She is a member of the Association of Clinical Research Professionals, a trade industry group. Butchertown Clinical Trials is an ophthalmic, primary care, nutrition, observational, and specimen clinical trial site. It has completed hundreds of clinical trials and has 21 FDA-approved drugs and devices. It is the largest and most successful privately operated ophthalmic clinical trial site in the U.S.

  • Butchertown Clinical Trials Promotes Olivia Kaiser to Clinical Trials Team Leader Louisville, Kentucky, May 8, 2024 Butchertown Clinical Trials, an outpatient clinical trials site, today announced Olivia Kaiser's promotion to Clinical Trials Team Leader. In this redesigned role, her responsibilities include scheduling resources and facilities and workflow management while she continues her recruiting role. Olivia has been integral to our development, and we are thrilled to promote her to this leadership position, said Mark Prussian, Co-Founder and CEO of Butchertown Clinical Trials. Ms. Kaiser joined the organization in 2023 and served as a Recruiter at Butchertown Clinical Trials, an affiliated company of The Eye Care Institute. She earned a Bachelor of Arts in Psychology from the University of Louisville and is a member of the Association of Clinical Research Professionals, a trade industry group. Butchertown Clinical Trials is an ambulatory clinical trial site in the Butchertown neighborhood of Louisville, KY. The company provides ophthalmology, optometry, and primary care clinical trials. With 21 FDA-approved drugs or devices, hundreds of trials completed, and 25 active trials, management believes Butchertown Clinical Trials is the largest and most successful privately owned ophthalmic clinical trials site in the US.   

  • So happy that Butchertown Clinical Trials was able to be a Phase III clinical trial site for this advancement in human health. This marks our 21st FDA approval!

    View organization page for Eyenovia, Inc., graphic

    7,312 followers

    Eyenovia Congratulates Formosa Pharmaceuticals, Inc. on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery. Eyenovia is thrilled to be Formosa's commercial partner for this product in the United States. Our CEO Michael Rowe added, "In addition to its many favorable clinical attributes, clobetasol propionate ophthalmic suspension 0.05% fits perfectly within our commercial strategy by allowing us to leverage our sales and distribution infrastructure." Eyenovia looks forward to making its partners across the globe proud. https://lnkd.in/gfr5XBt2

    • No alternative text description for this image

Similar pages

Browse jobs